|
Sign In to gain access to subscriptions and/or personal tools.
|
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data
Richard D. Storer
Merck & Co Inc, West Point, Pennsylvania 19486, richardstorer{at}merck.com
John E. French
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
Joseph Haseman
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
Gerald Hajian
Schering Plough Research Institute, Kenilworth, New Jersey 07083
Edmund K. Legrand
RW Johnson Pharmaceutical Research Institute, Raritan New Jersey 08869
Gerald G. Long
Eli Lilly & Co, Greenfield, Indiana 46140
Lori A. Mixson
Merck & Co Inc, West Point, Pennsylvania 19486
Ricardo Ochoa
Pfizer, Inc, Groton, Connecticut 06340
John E. Sagartz
Monsanto, St. Louis, MO 63141
Keith A. Soper
Merck & Co Inc, West Point, Pennsylvania 19486
The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17β-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-defi cient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed.
Key Words: p53 deficient • bioassay • short-term • 26-weeks • alternatives • carcinogenicity • testing.
Toxicologic Pathology, Vol. 29, No. 1 suppl,
30-50 (2001)
DOI: 10.1080/019262301753178465
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. J. Jonker, O. Bruning, M. van Iterson, M. M. Schaap, T. V. van der Hoeven, H. Vrieling, R. B. Beems, A. de Vries, H. van Steeg, T. M. Breit, et al.
Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models
Carcinogenesis,
October 1, 2009;
30(10):
1805 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kawasaki, Y. Hirabayashi, T. Kaneko, J. Kanno, Y. Kodama, Y. Matsushima, Y. Ogawa, M. Saitoh, K. Sekita, O. Uchida, et al.
Benzene-Induced Hematopoietic Neoplasms Including Myeloid Leukemia in Trp53-Deficient C57BL/6 and C3H/He Mice
Toxicol. Sci.,
August 1, 2009;
110(2):
293 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C.E. van Kesteren, R. B. Beems, M. Luijten, J. Robinson, A. de Vries, and H. van Steeg
DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?
Carcinogenesis,
March 1, 2009;
30(3):
538 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morton, K. L. Bailey, C. L. Stout, R. J. Weaver, K. A. White, M. J. Lorenzen, and D. J. Ball
N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/- Mouse Carcinogenicity Studies
Toxicol Pathol,
December 1, 2008;
36(7):
926 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kawai, M. Jin, J. Nishimura, Y. Dewa, Y. Saegusa, S. Matsumoto, E. Taniai, M. Shibutani, and K. Mitsumori
Hepatocarcinogenic Susceptibility of Fenofibrate and Its Possible Mechanism of Carcinogenicity in a Two-Stage Hepatocarcinogenesis Model of rasH2 Mice
Toxicol Pathol,
December 1, 2008;
36(7):
950 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams
Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals
Toxicol Pathol,
December 1, 2006;
34(7):
827 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. D. Johnson, L. Dooley, R. L. Morrissey, L. Arp, I. Kapetanovic, J. A. Crowell, and D. L. McCormick
Oncogenicity Evaluations of Chemopreventive Soy Components in p53(+/-) (p53 knockout) Mice
International Journal of Toxicology,
May 1, 2006;
25(3):
219 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Santostefano, D. J. Hoivik, and R. T. Miller
Investigations of Clofibrate in Alternative Carcinogenicity Models
International Journal of Toxicology,
September 1, 2005;
24(5):
285 - 288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, J. A. Campbell, D. J. Hoivik, R. T. Miller, J. S. Allen, P. C. Mann, K. Selinger, D. Rickert, P. M. Savina, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the p53+/- Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
289 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Nesfield, C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the rasH2 Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
301 - 311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, et al.
Evaluation of the Carcinogenic Potential of Clofibrate in FVB/Tg.AC Mouse After Oral Administration--Part I
International Journal of Toxicology,
September 1, 2005;
24(5):
313 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the FVB/Tg.AC Mouse After Dermal Application--Part II
International Journal of Toxicology,
September 1, 2005;
24(5):
327 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Nesfield, T. C. Williams, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, D. Rickert, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the Neonatal Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
341 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hoivik, J. S. Allen, H. G. Wall, J. B. Nold, R. T. Miller, and M. J. Santostefano
Studies Evaluating the Utility of N-Methyl-N-Nitrosourea as a Positive Control in Carcinogenicity Studies in the p53+/- Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
349 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. McAnulty and M. Skydsgaard
Diethylstilbestrol (DES): Carcinogenic Potential in Xpa-/-, Xpa-/-/p53+/-, and Wild-Type Mice During 9 Months' Dietary Exposure
Toxicol Pathol,
August 1, 2005;
33(5):
609 - 620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Elrick, J. A. Kramer, C. L. Alden, E. A. G. Blomme, R. T. Bunch, M. A. Cabonce, S. W. Curtiss, L. D. Kier, K. L. Kolaja, C. P. Rodi, et al.
Differential Display in Rat Livers Treated for 13 Weeks with Phenobarbital Implicates a Role for Metabolic and Oxidative Stress in Nongenotoxic Carcinogenicity
Toxicol Pathol,
January 1, 2005;
33(1):
118 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A.R. Lina, R. A. Woutersen, J. P. Bruijntjes, J. Van Benthem, J. A.H. Van Den Berg, J. Monbaliu, B. J.J.M. Thoolen, R. B. Beems, and C. F. Van Kreijl
Evaluation of the Xpa-Deficient Transgenic Mouse Model for Short-Term Carcinogenicity Testing: 9-Month Studies with Haloperidol, Reserpine, Phenacetin, and D-Mannitol
Toxicol Pathol,
February 1, 2004;
32(2):
192 - 201.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models
Toxicol Pathol,
February 1, 2003;
31(2):
254 - 257.
[PDF]
|
|
|
|
|
